Notes

Slide Show

Outline

1
2	Safe Harbor
3	Company Overview Strength in Diversity
4	Company Overview Aligned Interests
5	Company Overview – Pre Acquisition Diverse revenue stream
6	Diagnostic Industry Overview
7	Growth Objectives & Strategy
8	Sales & Marketing Strategy Direct USA Germany UK Distributors Worldwide Strategy System Selling Optimise distribution channels Expansion of customer base into new markets Investment US Sales & Marketing infrastructure now in place
9	Coagulation Market
10	Coagulation – Existing Trinity Business
11	bioMerieux Deal – Rationale
12	bioMerieux Deal – Rationale
13	bioMerieux Deal – Key Terms
14	bioMerieux Coagulation Product Line
15	Distribution Model Post Acquisition
16	Manufacturing Transfer / Integration Plan
17	Manufacturing Transfer / Integration Plan
18	Reorganisation Plan
19	Impact on Financials
20	Sources & Uses of Funds
21	HIV POC Test – US Market Recent announcement re 340B program Believed path for Bush $90m campaign Comparable margins to existing public health business
22	Investment Thesis Profitable and financially strong Eight consecutive years of growing revenues – CAGR 25% Geographic reach and product diversity Clear focus on business goals Consistently outperforming defensive growth market
23	"Q&A" Q&A